Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Other financing activities (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Other financing activities readings, the most recent being $229000.0 for Q4 2025.

  • Quarterly Other financing activities fell 26.84% to $229000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $235000.0 through Dec 2025, down 39.43% year-over-year, with the annual reading at $235000.0 for FY2025, 39.43% down from the prior year.
  • Other financing activities hit $229000.0 in Q4 2025 for Terns Pharmaceuticals, up from $6000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $1.7 million in Q2 2021 and bottomed at $6000.0 in Q1 2025.
  • Average Other financing activities over 5 years is $454333.3, with a median of $257000.0 recorded in 2022.
  • The largest annual shift saw Other financing activities skyrocketed 3024.24% in 2021 before it decreased 26.84% in 2025.
  • Terns Pharmaceuticals' Other financing activities stood at $1.7 million in 2021, then crashed by 84.79% to $257000.0 in 2022, then surged by 33.85% to $344000.0 in 2023, then dropped by 9.01% to $313000.0 in 2024, then dropped by 26.84% to $229000.0 in 2025.
  • Per Business Quant, the three most recent readings for TERN's Other financing activities are $229000.0 (Q4 2025), $6000.0 (Q1 2025), and $313000.0 (Q4 2024).